Samms, R. J., Cheng, C. C., Fourcaudot, M., Heikkinen, S., Khattab, A., Adams, J., Cersosimo, E., Triplitt, C., Puckett, C., Tsintzas, K., Adams, A. C., Abdul-Ghani, M. A., DeFronzo, R. A., & Norton, L. (2022). FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes. AJP - Endocrinology and Metabolism, 323(2), E123-E132. https://doi.org/10.1152/ajpendo.00050.2022